Antibiotics (Sep 2022)

In Vitro and In Vivo Antimicrobial Activity of the Novel Peptide OMN6 against Multidrug-Resistant <i>Acinetobacter baumannii</i>

  • Janna Michaeli,
  • Shira Mandel,
  • Shelly Maximov,
  • Jonathan Zazoun,
  • Paola Savoia,
  • Nimmi Kothari,
  • Thomas Valmont,
  • Livia Ferrari,
  • Leonard R. Duncan,
  • Stephen Hawser,
  • Moshe Cohen-Kutner,
  • Niv Bachnoff

DOI
https://doi.org/10.3390/antibiotics11091201
Journal volume & issue
Vol. 11, no. 9
p. 1201

Abstract

Read online

The rapid worldwide spread of antimicrobial resistance highlights the significant need for the development of innovative treatments to fight multidrug-resistant bacteria. This study describes the potent antimicrobial activity of the novel peptide OMN6 against a wide array of drug-resistant Acinetobacter baumannii clinical isolates. OMN6 prevented the growth of all tested isolates, regardless of any pre-existing resistance mechanisms. Moreover, in vitro serial-passaging studies demonstrated that no resistance developed against OMN6. Importantly, OMN6 was highly efficacious in treating animal models of lung and blood infections caused by multidrug-resistant A. baumannii. Taken together, these results point to OMN6 as a novel antimicrobial agent with the potential to treat life-threatening infections caused by multidrug-resistant A. baumannii avoiding resistance.

Keywords